Commercial FITs can match NG-MSDT diagnostic results for CRC by lowering the positivity threshold, enhancing sensitivity while maintaining specificity. FITs are accessible, noninvasive CRC screening ...

Noninvasive surveillance with multitarget stool DNA testing or fecal immunochemical testing (FIT) could potentially match colonoscopy for reducing long-term colorectal cancer (CRC) incidence and ...

Multitarget stool-based tests are showing promise for colorectal cancer (CRC) screening in average-risk individuals and could edge out the current standard fecal immunochemical test (FIT). These new ...

Results from a new JAMA Network study support the large-scale use of FIT tests. The findings show that those who complete one or more fecal immunochemical test (FIT) screenings are associated with a ...

Colorectal cancer continues to be one of the leading causes of cancer-related deaths worldwide. However, recent advancements in medical screening have brought new hope in the fight against this deadly ...

The U.S. Preventive Services Task Force recommends colorectal cancer screening for all adults starting at age 45. After age 75, the task force recommends talking with your health care team to decide ...

More than 10% of fecal immunochemical test (FIT)–based colorectal cancer screening could not be processed due to unsatisfactory samples. Colorectal cancer (CRC) screening using the fecal ...

Please provide your email address to receive an email when new articles are posted on . Multi-target stool DNA screening tests predicted neoplasia at follow-up colonoscopy more often than fecal ...

Please provide your email address to receive an email when new articles are posted on . In a prospective study, researchers enrolled 457 asymptomatic participants (mean age 61.4 years; 75% women) from ...

Commercially available noninvasive screening tests for colorectal cancer - a fecal immunochemical test (FIT) and the multi-target stool DNAtest (mt-sDNA; or Cologuard ®) - are equally effective for ...

In DID analysis, the rate of incidence was reduced by 0.34 cases per person-years in the screening group as compared with the historical FIT screening group (rate ratio [RR], 0.08 [95% CI, 0.07 to ...

MADISON, Wis., May 21, 2021 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) today highlights data from one oral and one poster presentation being featured at the 2021 Digestive Disease Week® (DDW® ...